Format

Send to

Choose Destination
Pancreas. 2018 Jul;47(6):738-741. doi: 10.1097/MPA.0000000000001077.

Comparison of Fasting Human Pancreatic Polypeptide Levels Among Patients With Pancreatic Ductal Adenocarcinoma, Chronic Pancreatitis, and Type 2 Diabetes Mellitus.

Author information

1
From the Divisions of Gastroenterology and Hepatology.
2
Biomedical Statistics and Informatics, and.
3
Endocrinology, Mayo Clinic, Rochester, MN.

Abstract

OBJECTIVES:

Human pancreatic polypeptide (HPP) is a hormone secreted by the ventral pancreas. While postprandial HPP levels have been studied in chronic pancreatitis (CP) and pancreatic ductal adenocarcinoma (PDAC), there are limited data on fasting HPP in these diseases.

METHODS:

Fasting serum HPP was measured in the following groups of patients: CP with diabetes mellitus (DM) (n = 16), CP without DM (n = 34), PDAC with new-onset DM (n = 50), PDAC without DM (n = 49), new-onset type 2 DM (n = 50), and controls without DM (n = 49). Sixty-six had type 3c DM (CP with DM, n = 16; PDAC with new-onset DM, n = 50).

RESULTS:

Median fasting HPP levels (in picograms per milliliter) were similar among all groups. Median (interquartile range) HPP levels in new-onset type 2 DM (n = 50; 288.3 [80.1-1072.1]) were similar to those in type 3c DM (n = 66; 242.3 [64.9-890.9]) (P = 0.71). In PDAC (n = 99), HPP values were similar in pancreatic head (n = 75) versus body/tail (n = 24) tumors (245.3 [64.3-1091.3] vs 334.7 [136.1-841.5]; P = 0.95), regardless of DM.

CONCLUSIONS:

Fasting HPP levels are similar in CP, PDAC, and controls regardless of glycemic status.

PMID:
29771765
PMCID:
PMC6139029
[Available on 2019-07-01]
DOI:
10.1097/MPA.0000000000001077
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center